Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22659959 | 0.83 | L3MBTL1 (0.47) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL1747540 | 0.80 | L3MBTL1 (0.47) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL13157188 | 0.80 | L3MBTL1 (0.47) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL5514021 | 0.79 | L3MBTL1 (0.53) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL22710167 | 0.79 | L3MBTL1 (0.53) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL4959971 | 0.79 | L3MBTL1 (0.53) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL28177022 | 0.79 | L3MBTL1 (0.53) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL7149877 | 0.79 | L3MBTL1 (0.53) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL13157184 | 0.76 | L3MBTL1 (0.44) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL1746441 | 0.76 | L3MBTL1 (0.44) | L3MBTL1MAPTTYRGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190264203-A1 | GLYCOCONJUGATES OF RNA INTERFERENCE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-10131907-B2 | Glycoconjugates of RNA interference agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20150065558-A1 | Glycoconjugates of RNA Interference Agents | BANK OF AMERICA, N.A. | 2015-03-05 | — | — | US | disclosed |
| US-8877917-B2 | Glycoconjugates of RNA interference agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20090203135-A1 | Glycoconjugates of RNA Interference Agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065558-A1 | Glycoconjugates of RNA Interference Agents | RNASE1, B3GAT3, UGCG | L3MBTL1 196/4885MAPT 4746/4885TYR 4607/4885 |
| US-10131907-B2 | Glycoconjugates of RNA interference agents | RNASE1, B3GAT3, UGCG | L3MBTL1 196/4885MAPT 4746/4885TYR 4607/4885 |
| US-20190264203-A1 | GLYCOCONJUGATES OF RNA INTERFERENCE AGENTS | RNASE1, B3GAT3, UGCG | L3MBTL1 196/4885MAPT 4746/4885TYR 4607/4885 |
| US-20090203135-A1 | Glycoconjugates of RNA Interference Agents | RNASE1, B3GAT3, UGCG | L3MBTL1 196/4885MAPT 4746/4885TYR 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.